Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

Pharmaceutical & Biologic Development

Active
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The Pharmaceutical and Biologic Development subcontract supports the Defense Health Agency and Department of Defense by developing and supplying critical medical materiel for prime contractors. The scope of work focuses on the formulation of sepsis treatments, wound infection prophylaxis, and prevention methods for Dengue fever and bacterial diarrhea. Deliverables include pharmacological reports, stability data, and prototype drug or biologic compounds. This opportunity is categorized under NAICS code 541714 and is based in Frederick. The solicitation was posted on August 7, 2026, with a response deadline of October 30, 2026.

General Info

Subcontract for developing medical materiel and treatments for DHA and DoD in Frederick.

Agency

Department Of Defense → Defense Health AgencyView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Frederick, MD, USA

Set-Aside

NONE

Documents

This scope was carved out of MTEC-26-04-MultiTopic.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

MTEC Solicitation Summary: Fiscal Year 2026 Multi-Topic Request for Project Proposals

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Health Agency
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Defense → Defense Health Agency
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Develops and supplies medical materiel for prime contractors on Defense Health Agency (DHA) projects. Formulates wound infection prophylaxis, sepsis treatments, and prevention methods for bacterial diarrhea and Dengue fever. Provides prototype drug/biologic compounds, stability data, and pharmacological reports.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Human Hindbrain Organoid Functional Assay Services.
Solicitation # RFQ_CDR-2026-135968
The U.S. Food and Drug Administration, through the Center for Drug Evaluation and Research, intends to award a sole-source, firm-fixed-price purchase order to OrganoTherapeutics SARL for human iPSC-derived hindbrain organoid functional assay services. This acquisition, conducted under FAR Part 12 as a commercial service, aims to support in vitro research on drug-induced effects on respiratory-relevant neural circuits. The scope of work includes the provision of human hindbrain organoids and associated culture materials, with twelve scheduled deliveries to the FDA White Oak Campus in Silver Spring, Maryland. The first delivery will consist of 96 organoids, followed by eleven subsequent deliveries of 48 organoids each. The contractor will perform functional characterization at its own laboratory using three-dimensional multi-electrode array technology to assess electrophysiological responses to FDA-identified drug and reversal-agent combinations. Key deliverables include the raw and analyzed data, analysis files, and comprehensive study reports. The anticipated period of performance is 18 months from the date of award. Award will be based on best value, with technical capability and past performance weighted more heavily than price. All invoicing must be processed electronically through the U.S. Department of Treasury's Invoice Processing Platform.
FDA Office Of Acq Grant Svcs

POSTED

about 18 hours ago

DEADLINE

in 5 days
View Details
NAICS: 541714
New
Federal
Hypoxia Chamber Services
Solicitation # 80JSC026Q0008
NASA Johnson Space Center is soliciting combined synopsis and request for quotations under solicitation 80JSC026Q0008 for Hypoxia Chamber Services to support the Artemis Program. The objective is to investigate the physiological, cognitive, and clinical effects of mild hypobaric hypoxia through two 7-day test protocols involving continuous habitation for six subjects at air equivalent altitudes of 7,000 and 9,500 feet. The scope of work encompasses the provision of infrastructure, personnel, training, materials, and operational support. The contract is structured as a firm fixed price agreement with a base period from September 15, 2026, to September 30, 2027, and multiple option periods extending through March 1, 2030. The acquisition is open to all responsible sources under NAICS code 541714, with a size standard of 1,000 employees. Evaluation is based on a trade-off process where technical acceptability and past performance are significantly more important than price. Proposals must be submitted via email to the designated points of contact by October 1, 2026, following an extension granted in Amendment 0004. Key requirements include the submission of FAR 52.212-3 representations and certifications and adherence to specific submission criteria regarding team qualifications and risk assessment. The contract also incorporates strict guidelines regarding the protection of sensitive information and restrictions on funding activities with China.
NASA Johnson Space Center

POSTED

1 day ago

DEADLINE

in 20 days
View Details
NAICS: 541714
New
Federal
Hypobaric Chamber Pilot Studies
Solicitation # 80JSC026Q0006
NASA Johnson Space Center is soliciting quotes under solicitation 80JSC026Q0006 for pilot hypobaric chamber testing facilities to support decompression sickness research. The primary objective is to validate non-NASA resources for safe prebreathe procedures and extravehicular activity to support Artemis mission planning. The base requirement consists of three test days, with a minimum of two subjects per day, collecting and recording data according to research protocols. The contract also includes six optional work items, including additional test days, inflight-like treatment preparation, elevated metabolic rate testing, pharmaceutical-enhanced prebreathe, and body temperature studies. The base period of performance runs from September 1, 2026, to September 30, 2027, with various option periods extending through March or September 2029. This is a small business set-aside acquisition under NAICS code 541714. Awards will be made based on a trade-off analysis where technical acceptability and past performance are significantly more important than price. Technical evaluation focuses on facility capabilities, medical support, team expertise, and the proposed schedule for subject throughput. Offerors must provide a price quotation using the provided pricing sheet, and quotes must remain valid for at least 90 days. Following several amendments, the final deadline for the submission of offers is October 1, 2026, at 1:00 p.m. Central Time. All submissions must be sent electronically to the designated points of contact.
NASA Johnson Space Center

POSTED

1 day ago

DEADLINE

in 20 days
View Details
NAICS: 541714
Federal
Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability (CADENCC)
Solicitation # W911SR-26-9-CADENCC
The Department of the Army, through the Army Contracting Command Edgewood Contracting Division and the Joint Project Lead Enabling Technologies, is seeking preproposals for the Chemical, Biological, Radiological and Nuclear Advance Defense Enabling Network and Clinical Capability project. This initiative aims to accelerate clinical trial startups for CBRN defense readiness by implementing Master Protocols, utilizing innovative technologies for decentralized trial operations, and establishing a pre-positioned clinical trial site network. The project will primarily focus on Phase I and Phase II clinical trials for early treatment products, post-exposure prophylaxis, and pre-exposure prophylaxis, including those under the Animal Rule. This opportunity is issued under 10 USC 4022 Other Transaction Authority for a prototype project, with the potential for non-competitive follow-on production contracts for successful performers. Preproposals are due by 1500 hours on September 17, 2026, and must be limited to 10 pages. Evaluation will be based on technical merit, military relevance, technology readiness level 4 or above, regulatory compliance with FDA guidelines, and best overall value. Prospective awardees must be registered in the System for Award Management database.
W6QK Acc-Apg

POSTED

8 days ago

DEADLINE

in 6 days
View Details

More opportunities from Department Of Defense → Defense Health Agency

Same awarding agency

NAICS: 339112
New
Federal
Draeger Perseus A500
Solicitation # HT940626QE112
The Defense Health Agency intends to award a firm-fixed-price, sole-source contract to Draeger Inc. for the procurement of seven Draeger Perseus A500 anesthesia workstations integrated with the Infinity Acute Care System (IACS). These units will serve as one-for-one replacements for end-of-life systems at Winn Army Community Hospital in Fort Stewart, Georgia, which have reached their ten-year service limit. The acquisition includes the necessary labor, travel for repairs and preventative maintenance, and parts to ensure optimized equipment uptime. Delivery is required within eight weeks of the order issuance. The sole-source justification is based on the need for clinical standardization, patient safety, and seamless integration with the Infinity M540 patient monitor and the Military Health System Genesis electronic health record. By utilizing the Draeger system, the government aims to avoid approximately 120,000 dollars in retraining costs and 45,000 dollars in redundant supply chain expenses. The procurement is categorized under NAICS code 339112 and is funded via the Defense Health Program. While the agency intends to negotiate with Draeger Inc., it is accepting capability statements from other authorized OEM dealers or distributors until September 13, 2026, to determine if a competitive procurement is warranted.
Surgical and Medical Instrument Manufacturing

POSTED

about 18 hours ago

DEADLINE

in 9 days
View Details

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 650+ contractors already using CLEATUS